How much revenue does Vitrolife AB (publ) make?

Vitrolife AB (publ) reported 3.44 billion SEK in revenue for fiscal year 2025, down 4.7% from 3.61 billion SEK in fiscal year 2024. In Q1 2026 revenue was 807.00 million SEK.

What is Vitrolife AB (publ)'s largest business segment?

Genetics, with 1.39 billion SEK or 40% of segment revenue in fiscal year 2025. Next: Consumables (40%) and Technologies (20%).

Where does Vitrolife AB (publ) make most of its revenue?

Europe, The Middle East and Africa: 29% of revenue by region in fiscal year 2025, followed by USA (21%).

What companies are similar to Vitrolife AB (publ)?

Listed companies of a similar size in the same industry (targeted healthcare equipment) include Getinge AB (publ) (GETI-B.ST), Sectra AB (publ) (SECT-B.ST), Elekta AB (publ) (EKTA-B.ST), Dynavox Group AB (publ) (DYVOX.ST).

Vitrolife AB (publ) (VITR.ST) Stock

About Vitrolife AB (publ)

Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware p...

At a glance

Vitrolife AB (publ) reported revenue of 3.44 billion SEK for fiscal year 2025, down 4.7% from fiscal year 2024, and net income of -5.01 billion SEK. In Q1 2026 (the quarter ended March 31, 2026) revenue was 807.00 million SEK, down 4.2% from a year before. Its largest business segment, Genetics, brought in 40% of segment revenue in fiscal year 2025; Europe, The Middle East and Africa was the largest region with 29%.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.